Sign in to fuzzto save your conversations, follow your research and come back anytime.
Solara Active Pharma Sciences
SectorHealthcare
In the news
Solara Active Pharma shares surge 16% on Q2 turnaround
Trading Ideas: 12 Stocks for September 15 Amid Market Pressure
Solara Active Pharma gets ₹162-crore tax demand reduced to zero
Solara Active Pharma shares jump 5% as Q1 profit rises 55% to ₹16.31 cr
Solara Active Pharma Sciences Stock Surges 10.28% Despite Rating Downgrade
Solara Active Pharma Sciences posts ₹9.60 cr Q4 profit, stock gains 1.36%
Solara Active Q4 profit jumps ₹9.7 crore, stock surges 15%
The Quarter story
The two most recent quarterly results, compared side-by-side.
Revenue and earnings recover, but core margins and debt mix need watching
Consolidated revenue grew from ₹3,201 in Q1 FY26 to ₹4,178 in Q2 FY27 — top line expanded
Base business EBITDA margin slipped from 25.9% in Q4 FY26 to 23.6% in Q2 FY27 — core profitability is softer
Consolidated EBITDA rose from ₹575 in Q1 FY26 to ₹769 in Q2 FY27 — operating profit recovered
Term loan rose from ₹1,754 in Q1 FY26 to ₹2,290 in Q2 FY27 — long-term borrowing increased
EPS climbed from ₹2.46 in Q1 FY26 to ₹5.92 in Q2 FY27 — earnings per share improved sharply
Net non-current assets moved from -₹135 in Q1 FY26 to -₹224 in Q2 FY27 — non-current position weakened
Net debt to EBITDA fell from 2.7x in Q1 FY26 to 1.8x in Q2 FY27 — leverage improved
Ibuprofen EBITDA improved from -₹179 in Q4 FY26 to -₹2 in Q2 FY27 but remains negative — segment is still loss-making
Finance costs fell from ₹234 in Q1 FY26 to ₹173 in Q2 FY27 — interest burden eased